Close Notification

Your cart does not contain any items

Venture Capital and the European Biotechnology Industry

W. Bains

$385.95   $346.95


Not in-store but you can order this
How long will it take?


Palgrave Macmillan
20 November 2008
This book opens up the world on private equity investment in one of the hottest industries - Biotechnology. The book describes how Europe has fallen behind the US due to under-investment and bad management by the VCs who control the companies. Detailed analysis shows why it is in VCs' interests to damage the very companies they invest in.
By:   W. Bains
Imprint:   Palgrave Macmillan
Country of Publication:   United Kingdom
Dimensions:   Height: 216mm,  Width: 140mm,  Spine: 14mm
Weight:   420g
ISBN:   9780230217195
ISBN 10:   0230217192
Pages:   220
Publication Date:   20 November 2008
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active
Introduction: The Facts The Biotechnology Industry and Venture Capital Europe Falls Behind Why Does Europe Do So Poorly? Some Inadequate Explanations Under-investment In European Biotechnology Public Markets and Under-investment VC Management of Companies VC Effects on Business Efficacy Investor Blockade of Business Pomp and Circumstances The Real VC Business Model What to do about it: Government What to do about it: Business References Index

WILLIAM BAINS is an academic and entrepreneur with experience in research, company creation and venture capital. He has founded four biotechnology companies, helped found and finance another ten, and is internationally recognized both as an innovator in biotechnology and a translator of innovation into business. He has written over 100 papers and teaches on innovation and entrepreneurship at Cambridge University, UK.

Reviews for Venture Capital and the European Biotechnology Industry

'With this well-referenced book Dr Bains has filled an important lacuna within the literature on European biotech VC [venture capital] financing with an accessible primer for MBA students particularly those researching biopharma and VC business cases and for students undertaking specialist, industry-focused, post-graduate courses.' Gerhard Symons, Pharmaceutical Executive Europe

See Also